

Final Report - Project 1

Caroline Ledbetter

Introduction

Study design

The data for this project come from the Childhood Asthma Management Program (CAMP), a clinical trial carried out in children with asthma. The trial was designed to determine the long-term effects of 3 treatments (budesonide, nedocromil, or placebo) on pulmonary function as measured by normalized FEV1 over a 5-6.5 year period. The design of CAMP was a multicenter, masked, placebo-controlled, randomized trial. A total of 695 children (210 in the budesonide group, 210 in the nedocromil group and 275 in the placebo group) aged 5-12 years were enrolled between December of 1993 and September of 1995. The primary outcome of the trial was lung function as measured by the Forced Expiratory Volume at 1 second (FEV1).

Research Question

The primary research question is whether or not children who use budesonide or nedocromil have better lung function as measured by FEV1. The primary hypothesis is that children who use budesonide or nedocromil have a significant better FEV1 at $\alpha = 0.05$.

The secondary research question is whether or not treatment is less effective in children whose parent smoke. The secondary hypothesis is that interaction between treatment group and whether or not a parent smoked in the home is not zero at $\alpha = 0.05$.

Methods

Data

This data set contained multiple observations for each subject ranging in number from 1 to 18 with an average of 14.31 observations (Fig 1).




Figure 1: Observations per Subject

Follow up visits ranged from 0 to 120 months (Fig 2). Since the primary research question was interested in improvement after 6 years, all observations after 72 months were excluded. The last observation with a pre-bronchodilator FEV measurement was then used for analysis of the outcome. A baseline FEV measurement

was obtained from the visit at 0 months of follow up. Subjects with no baseline or who only had a baseline observation were excluded. 4 subjects were excluded.

Information on age of the home, pets, woodstoves, dehumidifiers and smokers was not collected at every visit and had the potential to change over the course of the study, therefore whether or not the child ever reported the exposure during the first 6 years of follow-up was determined. Subjects who had no information (all missing values) on a variable over the 72 months were treated as missing, otherwise any subject who ever reported that exposure was a yes. Age of home was broken into two categorical variables by whether or not the child ever reported living in a home older than 50 years, and older than 100 years.




Figure 2: No. of Ids with observations at each time period

Analysis

Linear regression was used for all models and analysis. For the primary research question a crude model with only the outcome and exposure(treatment group) was analyzed. An adjusted model that included baseline FEV and covariates that were significantly different across treatment groups was also evaluated. A partial F test that compared the full adjusted model to a reduced model that did not include treatment groups was used to determine if there was a significant difference in treatment groups after adjusting for covariates.

For the secondary research question a partial F test was used to determine if the interaction between the treatment group and whether a parent had ever smoked was not zero. The full model included treatment group, whether a parent ever smoked and the interaction term. The reduced model was the full model minus the interaction term.

Results

Most characteristics of study participants were well distributed across treatment groups, with exception of gender which was found to significantly vary. (Table 1)

Table 1: Characteristics of Study Participants by Treatment Group

	Budesonide (n=208)	Nedocromil (n=209)	Placebo (n=274)	p-value
	N(%)	N(%)	N(%)	
Gender				0.01
Male	125(60)	139(67)	146(53)	
House >= 50				0.56
Yes	70(34)	66(32)	99(36)	

	Budesonide (n=208)	Nedocromil (n=209)	Placebo (n=274)	p-value
House \geq 100				0.97
Yes	12(6)	11(5)	15(5)	
Pets				0.34
Yes	179(86)	188(90)	235(86)	
Woodstove				0.95
Yes	24(12)	26(12)	34(12)	
Dehumidifier				0.41
Yes	31(15)	40(19)	53(19)	
Parents Smoke				0.68
Yes	76(37)	70(33)	90(33)	
Anyone Smokes				0.49
Yes	86(41)	78(37)	99(36)	
Ethnicity				0.95
Black	27(13)	27(11)	34(8)	
Hispanic	20(13)	23(9)	25(67)	
Other	21(12)	17(10)	21(68)	
Non-Hispanic White	140(10)	142(8)	194(71)	
	Mean(SD)	Mean(SD)	Mean(SD)	
Age at Enrollment	8.5(2.1)	8.3(2.2)	8.3(2.2)	0.64
Baseline FEV	1.7(0.5)	1.6(0.5)	1.7(0.5)	0.23
Months of Followup	68(11)	67(13)	68(12)	0.51

There was no significant difference in FEV measurements across treatment groups ($p=0.7029$) even after adjusting for baseline measurements and gender ($p=0.6322$).

The interaction between treatment group and whether the parent ever smoked in the home was not significant ($p=0.8133$).